Global Antibody-drug Conjugates Market and Forecast 2020-2026

                                          
A recently published report by Trusted Business Insights titled Global Antibody-drug Conjugates Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Antibody-drug Conjugates market. Trusted Business Insights report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.

Trusted Business Insights aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.

Report Overview:


Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

The global Antibody-drug Conjugates market size is projected to reach US$ 3262.1 million by 2026, from US$ 2731.9 million in 2020, at a CAGR of 3.0% during 2021-2026.

The global Antibody-drug Conjugates market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antibody-drug Conjugates market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

North America ranks the top in terms of global market size of Antibody Drug Conjugate, it consists of 59.12% of the international market in 2016. Europe comes the second, with 27.70% of the global market. Asia Pacific consists of 6.54%of the Antibody Drug Conjugate market in the same year.

Introduction to Brentuximab vedotin(Adcetris) and mechanism of action:

Brentuximab vedotin(SGN-35), also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.

Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis.

Brentuximab vedotin causes apoptosis of tumor cells by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtuble network, thus preventing tumor growth and proliferation.

Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens.

Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrated meaningful progress in treatment for patients affected by this disease.

Introduction to Trastuzumab emtansine(Kadcyla) and mechanism of action:

Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative) to produce cell cycle arrest and apoptosis. Even though it involves cell death, apoptosis serves a healthy and protective role in our bodies.

Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate made up of trastuzumab, stably linked to a highly potent chemotherapy (DM1) derived from maytansine. The developmental history of T-DM1 reaches back to the 1970s when the National Cancer Institute(US) sponsored a plant screening program where plant-derived compounds were tested for activity against cancer cell lines.

Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

Geographical Analysis:

Based on region, the global Antibody-drug Conjugates market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.

Key Players:

The major players that are operating in the global Antibody-drug Conjugates market are:

 	
ImmunoGen
 	
Seattle Genetics
 	
Roche
 	
Takeda

Segment by Type

 	
Adcetris
 	
Kadcyla

Segment by Application

 	
Breast Cancer
 	
Lymphoma

Competitive Landscape:

Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Antibody-drug Conjugates market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.

Seagen with Takeda Pharmaceuticals is conducting below studies and are in various Clinical Phases (Updated September 2020)

 	
R/R Diffuse Large B-Cell Lymphoma (SGN35-31: + lenalidomide, rituximab) (Phase3)
 	
1L Hodgkin lymphoma (HL) SGN35-27: + nivolumab, doxorubicin and dacarbazine (Phase 2)
 	
1L HL or PTCL (unfit for combination chemotherapy) SGN35-15: Monotherapy (Phase 2)
 	
R/R HL and PTCL SGN35-28: Retreatment (Phase 2)
 	
R/R HL (pediatrics) CheckMate 744: + nivolumab (Phase 2)

The report covers the following objectives:

• Proliferation and maturation of trade in the global Antibody-drug Conjugates market.

• The market share of the global Antibody-drug Conjugates market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.

• Current and future market trends that are influencing the growth opportunities and growth rate of the global Antibody-drug Conjugates market.

• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Antibody-drug Conjugates market.

In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion.

In April 2020, Shanghai Henlius Biopharmaceutical Co., Ltd. a wholly-owned subsidiary of the Company, received two Certificates of GMP Compliance of a Manufacturer from Poland’s Chief Pharmaceutical Inspector. The Company’s drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar at Xuhui District, Shanghai has successfully passed the Good Manufacturing Practice (GMP) on-site inspection by the EU. In May 2020, the MAA of HLX02 submitted by Accord Healthcare S.L.U. has adopted a positive opinion and recommended approval for MAA from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).